Current Report Filing (8-k)
23 December 2022 - 08:46AM
Edgar (US Regulatory)
0000012239 false --12-31 0000012239
2022-12-22 2022-12-22 iso4217:USD xbrli:shares iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or Section 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
December 22, 2022
Dominari Holdings Inc.
(Exact name of registrant as specified in its charter)
|
Delaware |
|
000-05576 |
|
52-0849320 |
(State
or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(IRS
Employer
Identification No.) |
One Rockefeller Plaza,
11 th Floor
New York,
NY
10020
(703) 992-9325
(Address, including Zip Code and Telephone Number, including
Area Code, of Principal Executive Offices)
AIkido Pharma Inc.
(Former name or former address, if changed since last report)
Check the appropriate box below if
the Form 8-K filing is intended to simultaneously
satisfy the filing obligation to the registrant under any of the
following provisions:
|
☐ |
Written communications
pursuant to Rule 425 under the Securities Act
(17 CFR 230.425) |
|
☐ |
Soliciting material
pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12) |
|
☐ |
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b)) |
|
☐ |
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
|
Common Stock, $0.0001 par value |
|
DOMH |
|
The
Nasdaq Capital Market |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this
chapter).
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Item 5.03 Amendments to Articles of Incorporation or Bylaws;
Change in Fiscal Year
Effective December 22, 2022, AIkido Pharma Inc. (the
“Company”) filed an amendment to its certificate of
incorporation, as amended, with the Secretary of State of Delaware
to change its corporate name from “AIkido Pharma Inc.” to “Dominari
Holdings Inc.” (the “Name Change Amendment”). The Name
Change Amendment was previously approved by the Company’s board of
directors on December 5, 2022. The Name Change Amendment is filed
as Exhibit 3.1 to this Current Report.
Item 7.01 Regulation FD Disclosure
On December 22, 2022, the Company issued a press release regarding
the change in its corporate name and also a change in the Company’s
trading symbol from “AIKI” to “DOMH”, effective with the opening of
trading on December 22, 2022. A copy of such press release is filed
as Exhibit 99.1 to this Current Report.
Item 9.01. Financial Statements and Exhibits.
Set forth below is a list of Exhibits included as part of this
Current Report.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
| Dated:
December 22, 2022 |
DOMINARI
HOLDINGS INC. |
| |
|
|
| |
By: |
/s/
Anthony Hayes |
| |
Name: |
Anthony
Hayes |
| |
Title: |
Chief
Executive Officer |
2
Alkido Pharma (NASDAQ:AIKI)
Historical Stock Chart
From May 2023 to Jun 2023
Alkido Pharma (NASDAQ:AIKI)
Historical Stock Chart
From Jun 2022 to Jun 2023
